Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone858-412-5302
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees11
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable
Equillium (NYSE:EQ) Frequently Asked Questions
What is Equillium's stock symbol?
Equillium trades on the New York Stock Exchange (NYSE) under the ticker symbol "EQ."
How were Equillium's earnings last quarter?
Equillium (NYSE:EQ) released its earnings results on Tuesday, November, 12th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.05. View Equillium's Earnings History.
When is Equillium's next earnings date?
What price target have analysts set for EQ?
3 Wall Street analysts have issued twelve-month price targets for Equillium's stock. Their forecasts range from $14.00 to $16.00. On average, they anticipate Equillium's share price to reach $15.00 in the next year. This suggests a possible upside of 200.0% from the stock's current price. View Analyst Price Targets for Equillium.
What is the consensus analysts' recommendation for Equillium?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Equillium.
What are Wall Street analysts saying about Equillium stock?
Here are some recent quotes from research analysts about Equillium stock:
- 1. According to Zacks Investment Research, "Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States. " (12/3/2019)
- 2. HC Wainwright analysts commented, "We have assessed Equillium using a risk-adjusted net present value (rNPV) approach driven by a discounted cash flow (DCF) analysis. This yields a $326M total firm value, driven by the future royalty-based revenue from itolizumab in GvHD and asthma. We apply a discount rate of 12% and effective tax rate of 30% to all future cash flows. This translates into a price per share of $14, assuming 22.8M shares outstanding as of mid-2020." (8/13/2019)
Has Equillium been receiving favorable news coverage?
Media coverage about EQ stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Equillium earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Equillium.
Who are some of Equillium's key competitors?
Some companies that are related to Equillium include Pfenex (PFNX), Rafael (RFL), ProMetic Life Sciences (PLI), Theratechnologies (TH), Matinas BioPharma (MTNB), Exicure (XCUR), Enochian Biosciences (ENOB), CEL-SCI (CVM), Neuren Pharmaceuticals (NEU), Exicure (XCUR), Emblem (EMC), Monash IVF Group (MVF), Senesco Technologies (ELOX), Resverlogix (RVX) and Horizon Discovery Group (HZD).
What other stocks do shareholders of Equillium own?
Who are Equillium's key executives?
Equillium's management team includes the folowing people:
- Mr. Daniel Mark Bradbury, CEO & Chairman (Age 58)
- Dr. Stephen Connelly, Chief Scientific Officer & Director (Age 37)
- Dr. Krishna R. Polu, Chief Medical Officer (Age 46)
- Mr. Bruce D. Steel C.F.A., Co-Founder, Pres, Chief Bus. Officer & Director (Age 53)
- Mr. Jason A. Keyes, Chief Financial Officer (Age 48)
When did Equillium IPO?
(EQ) raised $70 million in an initial public offering on Friday, October 12th 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO.
Who are Equillium's major shareholders?
Which institutional investors are selling Equillium stock?
Which institutional investors are buying Equillium stock?
How do I buy shares of Equillium?
Shares of EQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Equillium's stock price today?
One share of EQ stock can currently be purchased for approximately $5.00.
How big of a company is Equillium?
What is Equillium's official website?
How can I contact Equillium?
The company can be reached via phone at 858-412-5302.
MarketBeat Community Rating for Equillium (NYSE EQ)
MarketBeat's community ratings are surveys of what our community members think about Equillium and other stocks. Vote "Outperform" if you believe EQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
